Inhibikase Therapeutics Inc (NASDAQ:IKT) shares are trading higher by 31.1% to $1.56 during Wednesday’s session after the company announced the pricing of an approximately $110 million private placement financing. What Else: Inhibikase says the funds will support a Phase 2b trial for pulmonary arterial hypertension (PAH) and general corporate needs. Led by Soleus Capital and joined by investors such as Sands Capital and Blackstone, the deal involves the sale of common stock, pre-funded warrants and accompanying Series A-1 and B-1 warrants. As part of the transaction, two board members will res…